A Comparative Clinical Trial to Evaluate the Safety and Clinical Equivalence of Clotrimazole Troche/Lozenges USP, 10mg (Unique Pharmaceutical Laboratories, India) With Clotrimazole Troche 10mg (Roxane Laboratories Inc., USA) in Subjects With Oropharyngeal Candidiasis. — TPC  

Oropharyngeal Candidiasis Clinical Trial

Official title: "A Multi-Centre, Randomized, Double Blind, Parallel-Group, Comparative Clinical Trial to Evaluate the Safety and Clinical Equivalence of Generic Clotrimazole Troche/Lozenges USP, 10mg (Unique Pharmaceutical Laboratories, India) to Clotrimazole Troche/Lozenges ® 10mg (Roxane Laboratories Inc., USA) in Subjects With Oropharyngeal Candidiasis ".

Status Recruiting

Clinical Trial Summary

The objectives of this study are to compare the efficacy and safety of Clotrimazole troche/ lozenges USP, 10 mg (Unique Pharmaceutical Laboratories, India) vs. Clotrimazole Troche/ Lozenges USP, 10 mg (Roxane Laboratories Inc., USA) in patients with oropharyngeal candidiasis, where this condition has been diagnosed by clinical examination and confirmed by fungal culture

Clinical Trial Description

This study is Randomized, Double Blind, Parallel, Comparative study. Approximately 26 study sites across India will participate in this study to complete sample size of 360 randomized subjects in order to achieve at least 250 per-protocol (PP) subjects.

Subjects would be assigned randomly to test product or reference product in 1:1 ratio.

Subjects with confirmed oral candidiasis by KOH smear/candidal culture will be given study medication 5 times a day for 14 consecutive days.

The schedule of the subject's visit at study site will be as follows:

1. Visit 1 - Screening visit (-7 Days).

2. Visit 2 - Randomization (Day 1).

3. Visit 3 - Follow Up (Day 8 (+2)).

4. Visit 4 - Follow Up (Day 15 (+2)).

5. Visit 5 - Follow Up/ End of study (Day 21 (+/-4)) Subjects with complete resolution of signs and symptoms of Oral Candidiasis on Day 21 (+/-4) will be considered as treatment success. ;

Related Conditions & MeSH terms

• Candidiasis
• Oropharyngeal Candidiasis

• NCT number: NCT02635438
• Study type: Interventional
• Source: Thinq Pharma-CRO Pte. Ltd.
• Contact: Kalpesh B Vispute, Medical
• Phone: +912225816882
• Email: kalpesh@thinqcro.com
• Status: Recruiting
• Phase: Phase 3
• Start date: December 2016
• Completion date: November 2018